We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
CRISPR Therapeutics AG (CRSP - Free Report) closed at $62.43 in the latest trading session, marking a +0.02% move from the prior day. This change outpaced the S&P 500's 0.43% loss on the day. Elsewhere, the Dow lost 0.34%, while the tech-heavy Nasdaq lost 0.62%.
Prior to today's trading, shares of the company had lost 4.03% over the past month. This has lagged the Medical sector's loss of 3.51% and was narrower than the S&P 500's loss of 6.57% in that time.
Investors will be hoping for strength from CRISPR Therapeutics AG as it approaches its next earnings release. The company is expected to report EPS of -$1.91, down 26.49% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $5.67 million, up 949.63% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$7.69 per share and revenue of $119.24 million, which would represent changes of -263.62% and -86.97%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for CRISPR Therapeutics AG. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 5.8% lower. CRISPR Therapeutics AG is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 157, putting it in the bottom 39% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know
CRISPR Therapeutics AG (CRSP - Free Report) closed at $62.43 in the latest trading session, marking a +0.02% move from the prior day. This change outpaced the S&P 500's 0.43% loss on the day. Elsewhere, the Dow lost 0.34%, while the tech-heavy Nasdaq lost 0.62%.
Prior to today's trading, shares of the company had lost 4.03% over the past month. This has lagged the Medical sector's loss of 3.51% and was narrower than the S&P 500's loss of 6.57% in that time.
Investors will be hoping for strength from CRISPR Therapeutics AG as it approaches its next earnings release. The company is expected to report EPS of -$1.91, down 26.49% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $5.67 million, up 949.63% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$7.69 per share and revenue of $119.24 million, which would represent changes of -263.62% and -86.97%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for CRISPR Therapeutics AG. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 5.8% lower. CRISPR Therapeutics AG is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 157, putting it in the bottom 39% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.